NCT04965935View on ClinicalTrials.gov

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 15, 2021

Primary Completion Date

August 30, 2024

Study Completion Date

August 30, 2024

Conditions
Kidney Transplant RecipientsPost-transplant Diabetes MellitusType 2 Diabetes
Interventions
DRUG

Dapagliflozin 10 MG Oral Tablet

Dapagliflozin will be administered in a dose of 10 mg/day for 12 weeks.

DRUG

Placebo Matching Dapagliflozin Oral Tablet

Placebo will be administered for 12 weeks.

Trial Locations (1)

Unknown

Renal Physiology Laboratory, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER